Pfizer closes plant in India after several regulators find problems
(By Ed Silverman for ST A T) M ore than a year after spending roughly $17 billion to acquire Hospira,
Read More(By Ed Silverman for ST A T) M ore than a year after spending roughly $17 billion to acquire Hospira,
Read More(By Shefali Luthra for Kaiser Health News) You have your red pill and your green pill. There’s the one you
Read More(By Ed Silverman for ST A T) I n a stunning setback for Bristol-Myers Squibb, its blockbuster Opdivo medicine failed
Read More(By Karen Shakerdge, Side Effects Public Media, for Kaiser Health News) In a big hotel conference room near New York’s
Read More(By Rob Waters for ST A T) M ick Phillips didn’t think much about it when he started coughing a
Read MoreSome doctors and their staff are finding the health insurance prior authorization process to treat patients with opiate addiction it’s
Read More(By Ed Silverman for ST A T) E ven though various federal laws were designed to promote clinical trials for
Read More(By Ed Silverman for ST A T) After the Obama administration proposed overhauling Medicare Part B earlier this year, a
Read More(By Meghana Keshavan for ST A T) S hould researchers make public all the data they collect when testing drugs
Read MoreIn response to rising cost of prescription drugs, a handful of organizations have developed frameworks for assessing the value of
Read More